Oncology Clinical Trials

PharmaNet’s strong global oncology project teams combine on-staff oncologists with experienced directors, project managers, and CRAs. These dedicated project teams have conducted hundreds of regional and global oncology trials involving tens of thousands of patients and different classes of therapeutics, including cytotoxic chemotherapies, targeted therapeutics (including monoclonal antibodies), immunotherapies, pathway inhibitors, and therapeutic vaccines.

More than 200 clinical development programs in Phase I–Phase IV have been awarded to PharmaNet, including programs that led to eleven registration applications and seven NDA/MAA marketing approvals. More than 25 of the studies were for biologics, of which 18 of the studies involved monoclonal antibodies. For every project, the senior oncology leaders are aligned with the project teams, while each team is led by an experienced oncology project manager and staffed by monitors who specialize in oncology.

We leverage our diversified experience into one of the industry’s strongest oncology knowledge resources for outsourced clinical development. Our expertise is deployed to:

• Conduct your study in the most efficient way
• Build and strengthen positive relationships with key opinion leaders (KOLs), regulators, and oncology sites that meet enrollment objectives and provide high-quality data
• Provide you with engaged, accessible, and informed senior management

PharmaNet has extensive clinical research experience from first-in-man through Expanded Access Protocols (EAPs) in most solid tumor types including breast, lung, prostate, and colorectal and hematological malignancies (such as multiple myeloma and NHL). Project sizes range from local to regional to large, global programs.

Having established relationships with many of the world’s leading oncology institutions and experts in numerous indications, PharmaNet has the global resources to conduct programs wherever patient populations, economic conditions, and regulatory environment are most favorable.

HEMATOLOGIC MALIGNANCIES

PharmaNet has performed approximately 37 clinical trials for hematologic malignancies, involving 6,600 patients at approximately 1,800 sites. Our experience with hematologic malignancies includes:

SOLID TUMORS

 We were awarded more than 139 studies for solid tumor clinical trials, involving approximately 38,000 patients at 6,700 sites. Our experience with solid tumors includes:

SUPPORTIVE CARE

PharmaNet has executed more than 42 studies for supportive care in oncology, involving approximately 8,200 patients at 810 sites. These cover a variety of therapeutic categories associated with chemotherapy-related conditions. Our experience with supportive care includes:

• Breakthrough cancer pain
• Chemotherapy-induced rash
• Chemotherapy-induced nausea
• Therapy-related anemia
• Chemotherapy-induced neutropenia
• Chemotherapy-induced mucositis